bio-medicine.org

Share

bio-medicine.org

 •  September 23

HORSHAM, Pa., Sept. 22, 2017 /PRNewswire/ -- Janssen Biotech, Inc. (Janssen) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) seeking approval of sirukumab for the treatment of moderately to severely active rheumatoid arthritis (RA). The...

bio-medicine.org

 •  May 9

Toronto, Canada (PRWEB) May 09, 2017 In support of Arch Biopartners’ GMP manufacturing campaign for AB569, the company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs, Dalton will provide formulation development, cGMP powder and liquid filling, analytical method development and validation, and quality...

bio-medicine.org

 •  February 23

SAN DIEGO, Feb. 23, 2017 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company, announces that it has received notice from the U.S. Food and Drug Administration (FDA) authorizing the initiation a Phase I clinical trial with MVT-1075 as a therapeutic treatment for pancreatic cancer....